First released in November 2010, the SSE 380 index represents emerging blue-chip companies in the Shanghai securities market with good growth potential and strong profitability. These companies are moderately sized and have the potential to grow into blue-chip companies, representing the strategic direction of national economic development and the direction of economic restructuring. Now, HealthGen (600380) has also become a member of the potential growth blue-chip stocks.
It is understood that the main basis for the adjustment of the SSE index is the total market capitalization and trading volume over the past year, but different indices have different criteria. The SSE 380 index, to which HealthGen (600380) belongs, is composed of 380 stocks selected from A-shares listed on the Shanghai Stock Exchange, excluding the constituent stocks of the SSE 180 index. The selection is based on a comprehensive ranking of operating revenue growth rate, return on net assets, trading volume, and total market capitalization, and determined according to industry allocation principles.
Under this stock selection method, HealthGen (600380)'s inclusion in the SSE 380 index constituent stocks is an important reflection of the capital market's recognition of the company's investment value, demonstrating the capital market's full affirmation of HealthGen's operating performance, profitability, and growth potential, and reflecting the company's strong strength and development momentum.
As one of only 36 pharmaceutical and health industry stocks in the SSE 380 index, HealthGen (600380)'s leading industry position is further highlighted.
After years of operation and development, HealthGen has established a leading competitive advantage in the fields of chemical reagents, health products, diagnostic reagents, monoclonal antibodies, and raw materials. In addition, with the successful launch of two inhalers in 2019, HealthGen has continuously attracted investor attention. HealthGen has been very active in the capital market in recent months, first announcing a long-term partnership equity incentive plan, and then announcing a share repurchase plan of no more than 300 million yuan, reflecting the confidence of all employees in the company's long-term growth. This year, many securities firms have been optimistic about HealthGen's development prospects and given it a "buy" rating.
